During the past decade, Groupe hospitalier mutualiste Les Portes du sud conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 3 clinical trials were completed, i.e. on average, 27.3% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 3 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Groupe hospitalier mutualiste Les Portes du sud" #1 sponsor was "Eli Lilly and Company" with 5 trials, followed by "Centre Hospitalier Saint Joseph Saint Luc de Lyon" with 2 trials sponsored, "Ferring Pharmaceuticals" with 2 trials sponsored, "Hospices Civils de Lyon" with 2 trials sponsored and "Intergroupe Francophone de Cancerologie Thoracique" with 2 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Groupe hospitalier mutualiste Les Portes du sud" #1 collaborator was "Clinique du Val d'ouest" with 1 trials as a collaborator, "Hospira, now a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator and "Roche Diabetes Care France SAS" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Groupe hospitalier mutualiste Les Portes du sud" are "Ulcerative Colitis" (3 trials), "Obesity" (2 trials), "ALK Gene Mutation" (1 trials), "BRAF Gene Mutation" (1 trials) and "COVID-19" (1 trials). Many other conditions were trialed in "Groupe hospitalier mutualiste Les Portes du sud" in a lesser frequency.

Most popular intervention types in "Groupe hospitalier mutualiste Les Portes du sud" are "Drug" (8 trials), "Other" (2 trials), "Procedure" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Tirzepatide" (4 trials), "Dulaglutide" (2 trials), "Placebo" (2 trials), "CT-P13" (1 trials) and "Control group" (1 trials). Other intervention names were less common.

The vast majority of trials in "Groupe hospitalier mutualiste Les Portes du sud" are 15 trials for "All" genders.

Currently, there are NaN active trials in "Groupe hospitalier mutualiste Les Portes du sud". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Groupe hospitalier mutualiste Les Portes du sud, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Groupe hospitalier mutualiste Les Portes du sud, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".